Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 326

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 326
---
 will file a definitive proxy statement within 120 days after the end of its fiscal year pursuant to Regulation 14A
(the Proxy Statement) for its annual meeting of stockholders, and certain information included in the Proxy Statement is incorporated
herein by reference.

Item 10. Directors, Executive Officers and
Corporate Governance

The information required by this Item 10 will be set forth in the
Proxy Statement and is incorporated in this Annual Report by reference.

Item 11. Executive Compensation

The information required by this item will be set forth in the Proxy Statement
and is incorporated in this Annual Report by reference.

Item 12. Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters

Equity Compensation Plan Information

The following table provides certain information
with respect to all of our compensation plans in effect as of December 31, 2024:

    Plan Category 
    (A) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights  
    (B) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights  
    (C) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column(A)) 
  
    Equity Compensation Plans approved by stockholders 
     7,203,307(1) 
    $8.29  
     137,218(2)
  
    Equity Compensation Plans not approved by stockholders 
     —  
     —  
     — 
  
    Total 
     7,203,307  
    $8.29  
     137,218 

(1)Consists
of shares subject to outstanding stock options, under the Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan (the “2021
Plan”), the 2019 Stock Incentive Plan (the “2019 Plan”) and INmune Bio Inc. 2017 Stock Incentive Plan (the “2017
Plan) some of which are vested and some of which remain subject to the vesting of the respective equity award.

(2)Consists
of shares available for future issuance under the 2021 Plan and the 2019 Plan.

Other

The other information required by this item will be set forth in the Proxy
Statement and is incorporated in this Annual Report by reference.

Item 13. Certain Relationships and Related
Transactions, and Director Independence

The information